Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12597

    +

    P3.10-005 - A Phase II Study of Amrubicin and Carboplatin for Previously Untreated Patients with Extensive-Disease Small Cell Lung Cancer (ID 314)

    09:30 - 09:30  |  Author(s): S. Kohno
    • Abstract

    Background
    Amrubicin and cisplatin are active in the treatment of small cell lung cancer (SCLC), and carboplatin is an analogue of cisplatin with less nonh ematological toxicity. To determine the efficacy and toxicity of amrubicin and carboplatin for previously untreated patients with extensive-disease (ED) SCLC.

    Methods
    Patients and methods: Thirty-five patients fulfilling the following eligibility criteria were enrolled: chemotherapy-naive, good performance status (PS 0-1), age < 76, extensive-disease, and adequate organ function. Based on the phase I study (J Thorac Oncol 4:741, 2009), the patients received amrubicin35mg/m[2] i.v. on days 1,2 and 3, and carboplatin AUC 5 i.v. on day 1. Four cycles of chemotherapy were repeated every 3 weeks.

    Results
    Results: Thirty-five patients we re eligible and 34 patients were assessable for response, toxicity and surviva l. Patients’ characteristics were as follows: male/female=27/8; PS 0/1=4/31; median age(range)=64(41-75); stage IV=35. The overall response was 81% (CR5, P R21, SD4, PD2, NE3). Grade 4 leukopenia, neutropenia, and thrombocytopenia occ urred in 11%, 60%, and 11%, respectively. There were no treatment-related deat h and pneumonitis. Three patients experienced hypotension for amrubicin infusi on reaction and two were terminated the study. The median overall survival tim e, and the 1-, 2- and 3-year survival rates were 15.6 months, 63%, 33% and 8%, respectively. The median progression-free survival time was 6.5 months.

    Conclusion
    Amrubicin and carboplatin was effective in untreated extensive-disease small cell lung cancer.